Study of the effect of inhibiting galanin in Alzheimer's disease induced in rats

European Journal of Pharmacology

Volumn 641, Issue 2-3, 2010, Pages 123-127

  Baraka, Azza ^a   ElGhotny, Samar ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Alzheimer's; Galanin; Glibenclamide; Glitazone

Indexed keywords

GALANIN; GLIBENCLAMIDE; GLUCOSE; PIOGLITAZONE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; LATENT PERIOD; LEARNING; MALE; MAZE TEST; MEMORY DISORDER; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TASK PERFORMANCE;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AVOIDANCE LEARNING; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GALANIN; GLYBURIDE; HIPPOCAMPUS; HYPOGLYCEMIC AGENTS; LEARNING; MALE; MEMORY; RATS; RATS, WISTAR; TAU PROTEINS; THIAZOLIDINEDIONES;

EID: 77954086355     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.05.030     Document Type: Article

References (46)

1. Ben-Ari Y. Galanin and glibenclamide modulate the anoxic release of glutamate in rat CA3 hippocampal neurons. Eur. J. Neurosci. 2006, 1:62-68.
2. Branchek T.A., Smith K.E., Gerald C., Walker M.W. Trends Pharmacol. Sci. 2000, 21:109-117.
3. Counts S.E., Perez S.E., Ginsberg S.D., De Lacalle S., Mufson E.J. Galanin in Alzheimer's disease. Mol. Interv. 2003, 3:137-156.
4. Counts S.E., Chen E.Y., Che S., Ikonomovic M.D. Galanin fiber hypertrophy within the cholinergic nucleus basalis during the progression of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 21:205-214.
5. Crawley J.N. Galanin impairs cognitive abilities in rodents: relevance to Alzheimer's disease. Cell Mol. Life Sci. 2008, 65:1836-1841.
6. De Felice F.G., Vieira M.N., Bomfim T.R., Decker H., Velasco P.T., Lambert M.P., Viola K.L., Zhao W.Q., Ferreira S.T., Klein W.L. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1971-1976.
7. de Weille J., Schmid-Antomarchi H., Fosset M., Lazdunski M. ATP- sensitive K+channels that are blocked by hypoglycemia-inducing sulfonylureas in insulin-secreting cells are activated by galanin, a hyperglycemia-inducing hormone. Proc. Natl. Acad. Sci. U. S. A. 1988, 85:1312-1316.
8. Ewert T.J., Gritman K.R., Bader M., Habecker B.A. Post-infarct cardiac sympathetic hyperactivity regulates galanin expression. Neurosci. Lett. 2008, 436:163-166.
9. Gleason T.C., Dreiling J.L., Crawley J.N. Rat strain differences in response to galanin on the Morris water task. Neuropeptides 1999, 33:265-270.
10. Guo L., Tabrizchi R. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol. Ther. 2006, 111:145-173.
11. Holemans S., Feron O., Octave J.N., Maloteaux J.M. Interaction of fluorescein derivatives with glibenclamide binding sites in rat brain. Neurosci. Lett. 1995, 183:183-186.
12. Jirikowski G.F. A non-surgical technique for accurate intracerebral injections in rat. J. Neurosci. Methods 1992, 42:115-118.
13. Kinney J.W., Starosta G., Holmes A., Wrenn C.C., Yang R.J., Harris A.P., Long K.C., Crawley J.N. Deficits in trace cued fear conditioning in galanin-treated rats and galanin-overexpressing transgenic mice. Learn. Mem. 2002, 9:178-190.
14. Kinney J.W., Sanchez-Alavez M., Barr A.M., Criado J.R., Crawley J.N., Behrens M.M., Henriksen S.J., Bartfai T. Impairment of memory consolidation by galanin correlates with in vivo inhibition of both LTP and CREB phosphorylation. Neurobiol. Learn. Mem. 2009, 92:429-438.
15. Landreth G., Jiang Q., Mandrekar S., Heneka M. PPAR gamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 2008, 5:481-489.
16. Lang R., Gundlach A.L., Kofler B. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacol. Ther. 2007, 115:177-207.
17. Lee H.K., Kumar P., Fu Q., Rosen K.M., Querfurth H.W. the insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol. Biol. Cell. 2009, 20:1533-1544.
18. Liao F.F., Xu H. Insulin Signaling in Sporadic Alzheimer's disease. Sci. Signal. 2009, 2:pe36.
19. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997, 47:29-35.
20. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430:631-639.
21. McDonald M.P., Crawley J.N. Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer's disease. J. Psychiatr. Neurosci. 1997, 22:303-317.
22. McLaughlin P.J., Robinson J.K. Galanin: Involvement in Behavior and Neuropathology, and Therapeutic Potential. Drug News Perspect. 2002, 15:647-653.
23. Mishra S.K., Aaronson P.I. Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K (+) current in rat aorta myocytes. Eur. J. Pharmacol. 1999, 386:121-125.
24. Mitsukawa K., Lu X., Bartfai T. Galanin, galanin receptors and drug targets. Cell. Mol. Life. Sci. 2008, 65:1796-1805.
25. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
26. Mudher A.K., Woolley S.T., Perry V.H., Greene J.R.T. Induction of hyperphosphorylated tau in living slices of rat hippocampal formation and subsequent detection using an ELISA. J. Neurosci. Methods 1999, 88:15-25.
27. Neumann K.F., Rojo L., Navarrete L.P., Farías G., Reyes P., Maccioni R.B. Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr. Alzheimer Res. 2008, 5:438-447.
28. Nitta A., Itoh A., Hasegawa T., Nabeshima T. Beta-amyloid protein-induced Alzheimer's disease animal model. Neurosci. Lett. 1994, 170:63-66.
29. Revill P., Moral M.A., Prous J.R. Impaired insulin signaling and the pathogenesis of Alzheimer's disease. Drugs Today 2006, 42:785.
30. Risner M.E., Saunders A.M., Altman J.F., Ormandy G.C., Craft S., Foley I.M., Zvartau-Hind M.E., Hosford D.A., Roses A.D. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics 2006, 6:246-254.
31. Schulte-Herbrüggen O., Jockers-Scherübl M.C., Hellweg R. Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr. Alzheimer Res. 2008, 5:38-44.
32. Senechal Y., Kelly P.H., Dev K.K. Amyloid precursor protein knockout mice show age-dependent deficits in passive avoidance learning. Behav. Brain Res. 2008, 186:126-132.
33. Shearman M.S., Ragan C.I., Iversen L.L. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of beta-amyloid-mediated cell death. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1470-1474.
34. Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002, 106:3126-3132.
35. 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol. Aging. 1997, 18:591-608.
36. Simard J.M., Yurovsky V., Tsymbalyuk N., Melnichenko L., Ivanova S., Gerzanich V. Protective effect of delayed treatment with low-dose glibenclamide in three models of ischemic stroke. Stroke 2009, 40:604-609.
37. Slingerland A.S., Hurkx W., Noordam K., Flanagan S.E., Jukema J.W., Meiners L.C., Bruining G.J., Hattersley A.T., Hadders-Algra M. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabet. Med. 2008, 25:277-281.
38. Stefani M.R., Gold P.E. Intrahippocampal infusions of K-ATP influence spontaneous alternation performance: relationships to acetylcholine release in the hippocampus. J. Neurosci. 2001, 21(2):609-614.
39. Stéphan A., Phillips A.G. A case for a transgenic animal model of Alzheimer's disease. Genes Brain Behav. 2005, 4:157-172.
40. Strachan M.W. Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochem. Soc. Trans. 2005, 33:1037-1040.
41. Tang C., Akabayashi A., Manitiu A., Leibowitz S.F. Hypothalamic galanin gene expression and peptide levels in relation to circulating insulin: possible role in energy balance. Neuroendocrinology 1997, 65:265-275.
42. Tsukuda K., Mogi M., Iwanami J., Min L.J., Sakat A., Jing F., Iwai M., Horiuchi M. Cognitive deficit in amyloid-{beta}-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-{gamma} activation. Hypertension 2009, 54:782-787.
43. Vrontakis M.E. Galanin: a biologically active peptide. Curr. Drug Targets CNS Neurol. Disord. 2002, 1:531-541.
44. Wang J., Leibowitz K.L. Central insulin inhibits hypothalamic galanin and neuropeptide Y gene expression and peptide release in intact rats. Brain Res. 1997, 777:231-236.
45. West M.J. Regionally specific loss of neurons in the aging human hippocampus. Neurobiol. Aging. 1993, 14:287-293.
46. Winer B.J. Statistical Principles in Experimental Design 1971, Mc Graw-Hill, New York. 2nd edition.